HCPCS Level II code J2790 denotes a full-dose 300 microgram (1500 I.U.) injection of Rho(D) immune globulin, a human-derived product used to prevent Rh alloimmunization. Nationally, this code matters for obstetric, postpartum and certain urgent exposure scenarios where preventing maternal sensitization to Rh-positive fetal or donor red blood cells is clinically important. Proper coding affects clinical workflows, inventory control and payer adjudication for a time-sensitive prophylactic intervention.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a national overview of clinical context and common settings of care, descriptions of typical billing practices, and summaries of payer coverage considerations and reimbursement benchmarks where available. The publication highlights coding guidance, common modifiers in use, and areas where policy updates or prior authorization requirements can affect access and billing. It also outlines implications for supply chain and administration timing in outpatient and hospital-based settings.

Intended for billing managers, clinicians, and policy analysts, the piece presents actionable reference material on coding J2790, billing environments, and payer contexts to support accurate claim submission and program oversight.